ResearcherSichuan UniversityNo recent work listed

Jing Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2565-9103; OpenAlex author ID A5101530005. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper

Papers 2

Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Co-author DOI 10.5301/tj.5000499 ↗
Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Co-author DOI 10.1007/s12032-015-0580-4 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Qiu Li · 2 shared papers, 2015–2016 · strength 0.11
- Paper Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. DOI 10.5301/tj.5000499 ↗
- Paper Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer ba… DOI 10.1007/s12032-015-0580-4 ↗
Jian Zhang · 2 shared papers, 2015–2016 · strength 0.11
- Paper Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. DOI 10.5301/tj.5000499 ↗
- Paper Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer ba… DOI 10.1007/s12032-015-0580-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.